Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1

References

• Kim TK, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3):172–183. doi:10.1053/j.seminhematol.2015.04.00326111464
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.27276561
   PubMed Web of Science ®Google Scholar
• O’Brien EC, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014.
   Google Scholar
• Kantarjian H. Acute myeloid leukemia – major progress over four decades and glimpses into the future. Am J Hematol. 2016;91(1):131–145. doi:10.1002/ajh.2424626598393
   PubMed Web of Science ®Google Scholar
• Liersch R, Carsten M€uller-Tidow WE, Berdel KU. Prognostic factors for acute myeloid leukaemia in adults – biological significance and clinical use. Br J Haematol. 2014;165:17–38. doi:10.1111/bjh.1275024484469
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, CD B. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra140618426376137
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Farina M, Boni M, Irene Dambruoso CC. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: a worthy endeavor? Am J Hematol. 2016;91(5):507–517. doi:10.1002/ajh.2431226822317
   PubMed Web of Science ®Google Scholar
• Béné MC, Grimwade D, Haferlach C, Haferlach T, Zini G, LeukemiaNet E. Leukemia diagnosis: today and tomorrow. Eur J Haematol. 2015;95(4):365–373. doi:10.1111/ejh.1260326110830
   PubMed Web of Science ®Google Scholar
• Jafarlou M, Baradaran B, Shanehbandi D, et al. siRNA-mediated inhibition of survivin gene enhances the anti-cancer effect of etoposide in U-937 acute myeloid leukemia cells. Cell Mol Biol. 2016;62(6):44–49.
   Web of Science ®Google Scholar
• Zaki Dizaji M, Seyed H G, Hosseini E, et al. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: the odd expression pattern of survivin-2α. Asia Pac J Clin Oncol. 2016.
   Web of Science ®Google Scholar
• Pazhang Y, Jaliani HZ, Mehdi Imani DH. Synergism between NF-kappa B inhibitor, celastrol, and XIAP inhibitor, embelin, in an acute myeloid leukemia cell line, HL-60. J Cancer Res Ther. 2017;12(1):155–160.
   Web of Science ®Google Scholar
• Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244(2):164–171. doi:10.1016/j.canlet.2006.03.00716621243
   PubMed Web of Science ®Google Scholar
• Huynh T, Walchli S, Sioud M. Transcriptional targeting of small interfering RNAs into cancer cells. Biochem Biophys Res Commun. 2006;350(4):854–859. doi:10.1016/j.bbrc.2006.09.12717034763
   PubMed Web of Science ®Google Scholar
• Friedrichs B, Siegel S, Andersen MH, Schmitz N, Zeis M. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma. 2006;47(6):978–985. doi:10.1080/1042819050046406216840186
   PubMed Web of Science ®Google Scholar
• Horii T, Arai Y, Yamazaki M, et al. Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering. Sci Rep. 2014;4:4513. doi:10.1038/srep0451324675426
   PubMed Web of Science ®Google Scholar
• Nakade S, Tsubota T, Sakane Y, et al. Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat Commun. 2014;5:5560. doi:10.1038/ncomms656025410609
   PubMed Web of Science ®Google Scholar
• Morita S, Noguchi H, Horii T, et al. Targeted DNA demethylation in vivo using dCas9–peptide repeat and scFv–TET1 catalytic domain fusions. Nat Biotechnol. 2016;34(10):1060–1065. doi:10.1038/nbt.365827571369
   PubMed Web of Science ®Google Scholar
• Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957–963. doi:10.1038/nmeth.264924076990
   PubMed Web of Science ®Google Scholar
• Haghshenas V, Fakhari S, Mirzaie S, et al. Glycyrrhetinic Acid inhibits cell growth and induces apoptosis in ovarian cancer a2780 cells. Adv Pharm Bull. 2014;4(Suppl 1):437–441. doi:10.5681/apb.2014.06425364659
   PubMedGoogle Scholar
• Pirzadeh S, Fakhari S, Jalili A, Mirzai S, Ghaderi B, Haghshenas V. Glycyrrhetinic acid induces apoptosis in leukemic HL60 cells through upregulating of CD95/CD178. Int J Mol Cell Med. 2014;3(4):272–278.25635254
   PubMedGoogle Scholar
• Wang S, Yingqi X, Chan HF, et al. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy. J Controlled Release. 2016;240:454–464. doi:10.1016/j.jconrel.2016.04.018
   PubMed Web of Science ®Google Scholar
• Feng W, Yoshida A, Ueda T. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun. 2013;435:52–57. doi:10.1016/j.bbrc.2013.04.03623618862
   PubMed Web of Science ®Google Scholar
• Serrano-López J, Serrano J, Figueroa V, et al. Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia. Haematologica. 2013;98:1877–1885. doi:10.3324/haematol.2013.08364223812937
   PubMed Web of Science ®Google Scholar
• Su S, Hu B, Shao J, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070. doi:10.1038/srep2007026818188
   PubMed Web of Science ®Google Scholar
• Narimani M, Sharifi M, Hakhamaneshi MS, et al. BIRC5 gene disruption via CRISPR/Cas9n platform suppress acute myelocytic leukemia progression. Iran Biomed J. 2019;23:369–378. doi:10.29252/ibj.23.6.36931104397
   PubMedGoogle Scholar
• Shoeneman JK, Ehrhart EJ III, Charles JB, Thamm HD. Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma. Vet Comp Oncol. 2014;14(2):e45–57. doi:10.1111/vco.1210424923332
   PubMed Web of Science ®Google Scholar
• Morrison DJ, Hogan LE, Condos G, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012;26:271–279.21844871
   PubMed Web of Science ®Google Scholar
• Xue J, Xie X-J, Lin M-F. Expression and clinical significance of antiapoptotic gene (Survivin) in NB4 and acute promyelocytic leukemia cells. Sci World J. 2012;2012.
   Google Scholar
• Mak CSL, Yung MMH, Hui LMN, et al. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 2017;16(1). doi:10.1186/s12943-017-0582-2
   Web of Science ®Google Scholar